Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


Articles published in J Neuroimmunol

Retrieve available abstracts of 158 articles:
HTML format
Text format



Single Articles


    April 2017
  1. JACOB S, Al-Kandari A, Alroughani R, Al-Temaimi R, et al
    Assessment of plasma biomarkers for their association with Multiple Sclerosis progression.
    J Neuroimmunol. 2017;305:5-8.
    PubMed     Text format     Abstract available


  2. BUTTARI F, Zagaglia S, Marciano L, Albanese M, et al
    TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2017;305:172-174.
    PubMed     Text format     Abstract available


  3. MUTO M, Mori M, Liu J, Uzawa A, et al
    Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity.
    J Neuroimmunol. 2017;305:131-134.
    PubMed     Text format     Abstract available


  4. MASUDA H, Mori M, Uchida T, Uzawa A, et al
    Soluble CD40 ligand contributes to blood-brain barrier breakdown and central nervous system inflammation in multiple sclerosis and neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2017;305:102-107.
    PubMed     Text format     Abstract available


    February 2017
  5. DEPAULA-SILVA AB, Hanak TJ, Libbey JE, Fujinami RS, et al
    Theiler's murine encephalomyelitis virus infection of SJL/J and C57BL/6J mice: Models for multiple sclerosis and epilepsy.
    J Neuroimmunol. 2017 Feb 12. pii: S0165-5728(16)30480.
    PubMed     Text format     Abstract available


    December 2016
  6. ANNUNZIATA P, Cioni C, Mugnaini C, Corelli F, et al
    Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.
    J Neuroimmunol. 2016 Dec 23. pii: S0165-5728(16)30274.
    PubMed     Text format     Abstract available


  7. PAOLICELLI D, Manni A, D'Onghia M, Direnzo V, et al
    Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
    J Neuroimmunol. 2016 Dec 21. pii: S0165-5728(16)30371.
    PubMed     Text format     Abstract available


  8. MATUTE-BLANCH C, Rio J, Villar LM, Midaglia L, et al
    Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 18. pii: S0165-5728(16)30310.
    PubMed     Text format     Abstract available


  9. VOLPE G, Bernstock JD, Peruzzotti-Jametti L, Pluchino S, et al
    Modulation of host immune responses following non-hematopoietic stem cell transplantation: Translational implications in progressive multiple sclerosis.
    J Neuroimmunol. 2016 Dec 15. pii: S0165-5728(16)30312.
    PubMed     Text format     Abstract available


  10. GORDON-LIPKIN E, Calabresi PA
    Optical coherence tomography: A quantitative tool to measure neurodegeneration and facilitate testing of novel treatments for tissue protection in multiple sclerosis.
    J Neuroimmunol. 2016 Dec 14. pii: S0165-5728(16)30447.
    PubMed     Text format     Abstract available


  11. HOSSAIN MJ, Tanasescu R, Gran B
    Innate immune regulation of autoimmunity in multiple sclerosis: Focus on the role of Toll-like receptor 2.
    J Neuroimmunol. 2016 Dec 13. pii: S0165-5728(16)30448.
    PubMed     Text format     Abstract available


    November 2016
  12. HAGHMORAD D, Mahmoudi MB, Salehipour Z, Jalayer Z, et al
    Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 26. pii: S0165-5728(16)30423.
    PubMed     Text format     Abstract available


  13. PROKOPOVA B, Hlavacova N, Vlcek M, Penesova A, et al
    Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis.
    J Neuroimmunol. 2016 Nov 19. pii: S0165-5728(16)30241.
    PubMed     Text format     Abstract available


  14. ACHIRON A, Zilkha-Falb R, Mashiach R, Gurevich M, et al
    RAM-589.555 a new Polymerase-1 inhibitor as innovative targeted-treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30209.
    PubMed     Text format     Abstract available


  15. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    Angiogenic factors are associated with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 17. pii: S0165-5728(16)30304.
    PubMed     Text format     Abstract available


  16. ZHANG Y, Liu G, Duan Y, Han X, et al
    Prevalence of Small Intestinal Bacterial Overgrowth in Multiple Sclerosis: a Case-Control Study from China.
    J Neuroimmunol. 2016 Nov 16. pii: S0165-5728(16)30187.
    PubMed     Text format     Abstract available


  17. MURIS AH, Smolders J, Rolf L, Thewissen M, et al
    Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study.
    J Neuroimmunol. 2016;300:47-56.
    PubMed     Text format     Abstract available


  18. DIAS-CARNEIRO RP, von Glehn F, Moraes AS, Boldrini VO, et al
    MRZH reaction increases sensitivity for intrathecal IgG synthesis in IgG Oligoclonal band negative Multiple Sclerosis patients.
    J Neuroimmunol. 2016;300:30-35.
    PubMed     Text format     Abstract available


  19. KALINOWSKA-LYSZCZARZ A, Michalak S, Pawlak MA, Losy J, et al
    Serum sPECAM-1 and sVCAM-1 levels are associated with conversion to multiple sclerosis in patients with optic neuritis.
    J Neuroimmunol. 2016;300:11-14.
    PubMed     Text format     Abstract available


  20. COVACU R, Brundin L
    Endogenous spinal cord stem cells in multiple sclerosis and its animal model.
    J Neuroimmunol. 2016 Nov 15. pii: S0165-5728(16)30403.
    PubMed     Text format     Abstract available


  21. HAAS J, Schwarz A, Korporal-Kuhnke M, Jarius S, et al
    Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis.
    J Neuroimmunol. 2016 Nov 2. pii: S0165-5728(16)30258.
    PubMed     Text format     Abstract available


  22. AHARONI R, Rosen C, Shezen E, Bar-Lev DD, et al
    Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016 Nov 1. pii: S0165-5728(16)30381.
    PubMed     Text format     Abstract available


    October 2016
  23. MELIEF J, Koper JW, Endert E, Moller HJ, et al
    Glucocorticoid receptor haplotypes conferring increased sensitivity (BclI and N363S) are associated with faster progression of multiple sclerosis.
    J Neuroimmunol. 2016;299:84-89.
    PubMed     Text format     Abstract available


  24. FENOGLIO C, De Riz M, Pietroboni AM, Calvi A, et al
    Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis.
    J Neuroimmunol. 2016;299:81-83.
    PubMed     Text format     Abstract available


  25. DA COSTA DS, Hygino J, Ferreira TB, Kasahara TM, et al
    Vitamin D modulates different IL-17-secreting T cell subsets in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:8-18.
    PubMed     Text format     Abstract available


  26. BRIKEN S, Rosenkranz SC, Keminer O, Patra S, et al
    Effects of exercise on Irisin, BDNF and IL-6 serum levels in patients with progressive multiple sclerosis.
    J Neuroimmunol. 2016;299:53-58.
    PubMed     Text format     Abstract available


  27. JONS D, Kneider M, Fogelstrand L, Jeppsson A, et al
    Early hematopoiesis in multiple sclerosis patients.
    J Neuroimmunol. 2016;299:158-163.
    PubMed     Text format     Abstract available


  28. DOOLEY MM, de Gannes SL, Fu KA, Lindsey JW, et al
    The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins.
    J Neuroimmunol. 2016;299:147-151.
    PubMed     Text format     Abstract available


  29. WALLER R, Woodroofe MN, Wharton SB, Ince PG, et al
    Gene expression profiling of the astrocyte transcriptome in multiple sclerosis normal appearing white matter reveals a neuroprotective role.
    J Neuroimmunol. 2016;299:139-146.
    PubMed     Text format     Abstract available


  30. MANE-MARTINEZ MA, Olsson B, Bau L, Matas E, et al
    Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
    J Neuroimmunol. 2016;299:112-117.
    PubMed     Text format     Abstract available


  31. CROSS AH, Song SK
    "A new imaging modality to non-invasively assess multiple sclerosis pathology".
    J Neuroimmunol. 2016 Oct 8. pii: S0165-5728(16)30328.
    PubMed     Text format     Abstract available


  32. REICH DS
    Imag(in)ing multiple sclerosis: Time to take better pictures.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30307.
    PubMed     Text format     Abstract available


  33. ITOH N, Kim R, Peng M, DiFilippo E, et al
    Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis.
    J Neuroimmunol. 2016 Oct 3. pii: S0165-5728(16)30308.
    PubMed     Text format     Abstract available


    September 2016
  34. BOIOCCHI C, Monti MC, Osera C, Mallucci G, et al
    Heat shock protein 70-hom gene polymorphism and protein expression in multiple sclerosis.
    J Neuroimmunol. 2016;298:189-93.
    PubMed     Text format     Abstract available


  35. TAO Y, Zhang X, Markovic-Plese S
    Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
    J Neuroimmunol. 2016;298:181-8.
    PubMed     Text format     Abstract available


  36. OZGUN-ACAR O, Celik-Turgut G, Gazioglu I, Kolak U, et al
    Capparis ovata treatment suppresses inflammatory cytokine expression and ameliorates experimental allergic encephalomyelitis model of multiple sclerosis in C57BL/6 mice.
    J Neuroimmunol. 2016;298:106-16.
    PubMed     Text format     Abstract available


  37. COSENTINO M, Zaffaroni M, Legnaro M, Bombelli R, et al
    Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis.
    J Neuroimmunol. 2016;298:82-9.
    PubMed     Text format     Abstract available


  38. MIYAZAKI Y, Niino M, Kanazawa I, Suzuki M, et al
    Fingolimod suppresses bone resorption in female patients with multiple sclerosis.
    J Neuroimmunol. 2016;298:24-31.
    PubMed     Text format     Abstract available


  39. EFTHYMIOU G, Dardiotis E, Liaskos C, Marou E, et al
    Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis: (ir)Relevance to disease pathogenesis.
    J Neuroimmunol. 2016;298:19-23.
    PubMed     Text format     Abstract available


  40. TANAKA M, Tanaka K
    Sudden hearing loss as the initial symptom in Japanese patients with multiple sclerosis and seropositive neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2016;298:16-8.
    PubMed     Text format     Abstract available


    August 2016
  41. ZHANG Y, Liu G, Han X, Dong H, et al
    The association of serum 25-hydroxyvitamin D levels with multiple sclerosis severity and progression in a case-control study from China.
    J Neuroimmunol. 2016;297:127-31.
    PubMed     Text format     Abstract available


  42. PUTHENPARAMPIL M, Miante S, Federle L, Zanetta C, et al
    BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset.
    J Neuroimmunol. 2016;297:63-7.
    PubMed     Text format     Abstract available


  43. CALA CM, Moseley CE, Steele C, Dowdy SM, et al
    T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis.
    J Neuroimmunol. 2016;297:1-8.
    PubMed     Text format     Abstract available


  44. LOVETT-RACKE AE
    Contribution of EAE to understanding and treating multiple sclerosis.
    J Neuroimmunol. 2016 Aug 12. pii: S0165-5728(16)30195.
    PubMed     Text format     Abstract available


    July 2016
  45. LEVIN MC, Lee S, Gardner LA, Shin Y, et al
    Autoantibodies to heterogeneous nuclear ribonuclear protein A1 (hnRNPA1) cause altered 'ribostasis' and neurodegeneration; the legacy of HAM/TSP as a model of progressive multiple sclerosis.
    J Neuroimmunol. 2016 Jul 17. pii: S0165-5728(16)30155.
    PubMed     Text format     Abstract available


  46. NIMMAGADDA VK, Makar TK, Chandrasekaran K, Sagi AR, et al
    SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.
    J Neuroimmunol. 2016 Jul 17. pii: S0165-5728(16)30158.
    PubMed     Text format     Abstract available


  47. VALENZUELA RM, Kaufman M, Balashov KE, Ito K, et al
    Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
    J Neuroimmunol. 2016 Jul 2. pii: S0165-5728(16)30137.
    PubMed     Text format     Abstract available


    June 2016
  48. MOHAMMADI N, Adib M, Alsahebfosoul F, Kazemi M, et al
    Corrigendum to "An investigation into the association between HLA-G 14bp insertion/deletion polymorphism and multiple sclerosis susceptibility" [Journal of Neuroimmunology 290 (2016) 115-118].
    J Neuroimmunol. 2016;295-296:164.
    PubMed     Text format    


  49. FAGONE P, Mangano K, Di Marco R, Touil-Boukoffa C, et al
    Corrigendum to "Expression of DNA methylation genes in secondary progressive multiple sclerosis" [J. Neuroimmunol. 290 (2016 Jan. 15) 66-9].
    J Neuroimmunol. 2016;295-296:163.
    PubMed     Text format    


  50. HUANG Q, Xiao B, Ma X, Qu M, et al
    MicroRNAs associated with the pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2016;295-296:148-61.
    PubMed     Text format     Abstract available


  51. ANSARI QESHMI S, Dabbagh F, Borhani Haghighi A, Ghasemi Y, et al
    Bioinformatics evaluation of the possibility of heat shock proteins as autoantigens in multiple sclerosis based on molecular mimicry hypothesis.
    J Neuroimmunol. 2016;295-296:100-21.
    PubMed     Text format     Abstract available


    May 2016
  52. RAINE CS
    Multiple sclerosis: The resolving lesion revealed.
    J Neuroimmunol. 2016 May 27. pii: S0165-5728(16)30129.
    PubMed     Text format     Abstract available


  53. CATANZARO G, Pucci M, Viscomi MT, Lanuti M, et al
    Epigenetic modifications of Dexras 1 along the nNOS pathway in an animal model of multiple sclerosis.
    J Neuroimmunol. 2016;294:32-40.
    PubMed     Text format     Abstract available


  54. HAAS J, Schwarz A, Korporal-Kuhnke M, Faller S, et al
    Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis.
    J Neuroimmunol. 2016;294:18-26.
    PubMed     Text format     Abstract available


  55. ERDUR H, Scholz V, Streitz M, Hammer M, et al
    EBNA1 antigen-specific CD8+ T cells in cerebrospinal fluid of patients with multiple sclerosis.
    J Neuroimmunol. 2016;294:14-7.
    PubMed     Text format     Abstract available


  56. RIZZO R, Bortolotti D, Fainardi E, Gentili V, et al
    KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
    J Neuroimmunol. 2016;294:1-5.
    PubMed     Text format     Abstract available


    April 2016
  57. ALVARENGA-FILHO H, Sacramento PM, Ferreira TB, Hygino J, et al
    Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators.
    J Neuroimmunol. 2016;293:91-9.
    PubMed     Text format     Abstract available


  58. YAMOUT B, Karaky NM, Mahfouz RA, Jaber F, et al
    Vitamin D receptor biochemical and genetic profiling and HLA-class II genotyping among Lebanese with multiple sclerosis - A pilot study.
    J Neuroimmunol. 2016;293:59-64.
    PubMed     Text format     Abstract available


    March 2016
  59. MELNIKOV M, Belousova O, Murugin V, Pashenkov capital EM, Cyrillic, et al
    The role of dopamine in modulation of Th-17 immune response in multiple sclerosis.
    J Neuroimmunol. 2016;292:97-101.
    PubMed     Text format     Abstract available


  60. SMOLDERS J, Muris AH, Damoiseaux J
    Immunomodulation by vitamin D in multiple sclerosis: More than IL-17.
    J Neuroimmunol. 2016;292:79-80.
    PubMed     Text format    


  61. MAGNER WJ, Weinstock-Guttman B, Rho M, Hojnacki D, et al
    Dicer and microRNA expression in multiple sclerosis and response to interferon therapy.
    J Neuroimmunol. 2016;292:68-78.
    PubMed     Text format     Abstract available


  62. BURMAN J, Raininko R, Blennow K, Zetterberg H, et al
    YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;292:52-7.
    PubMed     Text format     Abstract available


  63. BURMAN J, Svenningsson A
    Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;292:40-4.
    PubMed     Text format     Abstract available


  64. MARTIRE S, Navone ND, Montarolo F, Perga S, et al
    A gene expression study denies the ability of 25 candidate biomarkers to predict the interferon-beta treatment response in multiple sclerosis patients.
    J Neuroimmunol. 2016;292:34-9.
    PubMed     Text format     Abstract available


  65. MAKAR TK, Nimmagadda VK, Singh IS, Lam K, et al
    TrkB agonist, 7,8-dihydroxyflavone, reduces the clinical and pathological severity of a murine model of multiple sclerosis.
    J Neuroimmunol. 2016;292:9-20.
    PubMed     Text format     Abstract available


  66. MAUSNER-FAINBERG K, Kolb H, Penn M, Regev K, et al
    Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-beta.
    J Neuroimmunol. 2016;292:93-6.
    PubMed     Text format     Abstract available


    February 2016
  67. MATAS E, Bau L, Martinez-Iniesta M, Romero-Pinel L, et al
    MxA mRNA expression as a biomarker of interferon beta response in multiple sclerosis patients.
    J Neuroimmunol. 2016;291:73-7.
    PubMed     Text format     Abstract available


  68. FORWELL AL, Bernales CQ, Ross JP, Yee IM, et al
    Analysis of CH25H in multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2016;291:70-2.
    PubMed     Text format     Abstract available


  69. IRELAND SJ, Guzman AA, Frohman EM, Monson NL, et al
    B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses.
    J Neuroimmunol. 2016;291:46-53.
    PubMed     Text format     Abstract available


  70. MADEIRA A, Burgelin I, Perron H, Curtin F, et al
    MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment.
    J Neuroimmunol. 2016;291:29-38.
    PubMed     Text format     Abstract available


  71. ZAHEDNASAB H, Karampoor S
    The correlation of HLA-G with multiple sclerosis.
    J Neuroimmunol. 2016;291:28.
    PubMed     Text format    


  72. BLAIR TC, Manoharan M, Rawlings-Rhea SD, Tagge I, et al
    Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis.
    J Neuroimmunol. 2016;291:1-10.
    PubMed     Text format     Abstract available


  73. MIYAJI K, Paul F, Shahrizaila N, Umapathi T, et al
    Autoantibodies to tetraspanins (CD9, CD81 and CD82) in demyelinating diseases.
    J Neuroimmunol. 2016;291:78-81.
    PubMed     Text format     Abstract available


    January 2016
  74. MOHAMMADI N, Adib M, Alsahebfosoul F, Kazemi M, et al
    An investigation into the association between HLA-G 14bp insertion/deletion polymorphism and multiple sclerosis susceptibility.
    J Neuroimmunol. 2016;290:115-8.
    PubMed     Text format     Abstract available


  75. KHORRAMDELAZAD H, Bagheri V, Hassanshahi G, Zeinali M, et al
    New insights into the role of stromal cell-derived factor 1 (SDF-1/CXCL12) in the pathophysiology of multiple sclerosis.
    J Neuroimmunol. 2016;290:70-5.
    PubMed     Text format     Abstract available


  76. FAGONE P, Mangano K, Di Marco R, Touil-Boukoffa C, et al
    Expression of DNA methylation genes in secondary progressive multiple sclerosis.
    J Neuroimmunol. 2016;290:66-9.
    PubMed     Text format     Abstract available


  77. KARAMPOOR S, Zahednasab H, Ramagopalan S, Mehrpour M, et al
    25-hydroxyvitamin D levels are associated with multiple sclerosis in Iran: A cross-sectional study.
    J Neuroimmunol. 2016;290:47-8.
    PubMed     Text format     Abstract available


  78. HASSON T, Kolitz S, Towfic F, Laifenfeld D, et al
    Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
    J Neuroimmunol. 2016;290:84-95.
    PubMed     Text format     Abstract available


  79. MAURER MA, Tuller F, Gredler V, Berger T, et al
    Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.
    J Neuroimmunol. 2016;290:49-53.
    PubMed     Text format     Abstract available


    December 2015
  80. HORELLOU P, Wang M, Keo V, Chretien P, et al
    Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
    J Neuroimmunol. 2015;289:1-7.
    PubMed     Text format     Abstract available


  81. MOHAJERI M, Sadeghizadeh M, Javan M
    Pertussis toxin promotes relapsing-remitting experimental autoimmune encephalomyelitis in Lewis rats.
    J Neuroimmunol. 2015;289:105-10.
    PubMed     Text format     Abstract available


  82. YAMOUT BI, Zeineddine MM, Tamim H, Khoury SJ, et al
    Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East.
    J Neuroimmunol. 2015;289:93-7.
    PubMed     Text format     Abstract available


    November 2015
  83. KHOSRAVI A, Javan B, Tabatabaiefar MA, Ebadi H, et al
    Association of interleukin-1 gene cluster polymorphisms and haplotypes with multiple sclerosis in an Iranian population.
    J Neuroimmunol. 2015;288:114-9.
    PubMed     Text format     Abstract available


  84. NEGROTTO L, Canto E, Rio J, Tintore M, et al
    Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta.
    J Neuroimmunol. 2015;288:98-101.
    PubMed     Text format     Abstract available


  85. KVISTAD SS, Myhr KM, Holmoy T, Saltyte Benth J, et al
    Body mass index influence interferon-beta treatment response in multiple sclerosis.
    J Neuroimmunol. 2015;288:92-7.
    PubMed     Text format     Abstract available


  86. WAGNER M, Sobczynski M, Karabon L, Bilinska M, et al
    Polymorphisms in CD28, CTLA-4, CD80 and CD86 genes may influence the risk of multiple sclerosis and its age of onset.
    J Neuroimmunol. 2015;288:79-86.
    PubMed     Text format    


  87. LINSENBARDT HR, Cook JL, Young EE, Vichaya EG, et al
    Social disruption alters pain and cognition in an animal model of multiple sclerosis.
    J Neuroimmunol. 2015;288:56-68.
    PubMed     Text format     Abstract available


  88. TANAKA M, Kinoshita M
    Daily fingolimod administration may cause lymphopenia but alternate-day administration may be too little to inhibit disease activity.
    J Neuroimmunol. 2015;288:69.
    PubMed     Text format     Abstract available


    October 2015
  89. EHLING R, Di Pauli F, Lackner P, Rainer C, et al
    Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
    J Neuroimmunol. 2015;287:98-105.
    PubMed     Text format     Abstract available


  90. MACCHI B, Marino-Merlo F, Nocentini U, Pisani V, et al
    Role of inflammation and apoptosis in multiple sclerosis: Comparative analysis between the periphery and the central nervous system.
    J Neuroimmunol. 2015;287:80-7.
    PubMed     Text format     Abstract available


  91. DALLARI S, Franciotta D, Carluccio S, Signorini L, et al
    Upregulation of integrin expression on monocytes in multiple sclerosis patients treated with natalizumab.
    J Neuroimmunol. 2015;287:76-9.
    PubMed     Text format     Abstract available


  92. MILOSEVIC E, Dujmovic I, Markovic M, Mesaros S, et al
    Higher expression of IL-12Rbeta2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-beta1b therapy during 3-year follow-up.
    J Neuroimmunol. 2015;287:64-70.
    PubMed     Text format     Abstract available


  93. KEVIN LI-CHUN H, Schob S, Zeller MW, Pulli B, et al
    Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis.
    J Neuroimmunol. 2015;287:36-42.
    PubMed     Text format     Abstract available


  94. BEPPU M, Sawai S, Satoh M, Mori M, et al
    Autoantibodies against vinculin in patients with chronic inflammatory demyelinating polyneuropathy.
    J Neuroimmunol. 2015;287:9-15.
    PubMed     Text format     Abstract available


    September 2015
  95. MAUSNER-FAINBERG K, Regev K, Kolb H, Vaknin-Dembinsky A, et al
    Increased neutralization capacity of TNF-alpha in sera of relapsing remitting multiple sclerosis patients is not related to soluble TNF-alpha receptors or anti-TNF-alpha autoantibody levels.
    J Neuroimmunol. 2015;286:83-5.
    PubMed     Text format     Abstract available


  96. GASPAROVIC I, Cizmarevic NS, Lovrecic L, Perkovic O, et al
    MMP-2 -1575G/A polymorphism modifies the onset of optic neuritis as a first presenting symptom in MS?
    J Neuroimmunol. 2015;286:13-5.
    PubMed     Text format     Abstract available


    August 2015
  97. PFUHL C, Oechtering J, Rasche L, Giess RM, et al
    Association of serum Epstein-Barr nuclear antigen-1 antibodies and intrathecal immunoglobulin synthesis in early multiple sclerosis.
    J Neuroimmunol. 2015;285:156-60.
    PubMed     Text format     Abstract available


  98. TOGHIANIFAR N, Ashtari F, Zarkesh-Esfahani SH, Mansourian M, et al
    Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial.
    J Neuroimmunol. 2015;285:125-8.
    PubMed     Text format     Abstract available


  99. STASCHEIT F, Paul F, Harms L, Rosche B, et al
    Toxoplasma gondii seropositivity is negatively associated with multiple sclerosis.
    J Neuroimmunol. 2015;285:119-24.
    PubMed     Text format     Abstract available


  100. DERFUSS T, Curtin F, Guebelin C, Bridel C, et al
    A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.
    J Neuroimmunol. 2015;285:68-70.
    PubMed     Text format     Abstract available


  101. AL-TEMAIMI R, Alroughani R, Jacob S, Al-Mulla F, et al
    Gender influence in EBV antibody response in multiple sclerosis patients from Kuwait.
    J Neuroimmunol. 2015;285:57-61.
    PubMed     Text format     Abstract available


  102. YAMOUT BI, Zeineddine MM, Sawaya RA, Khoury SJ, et al
    Safety and efficacy of reduced fingolimod dosage treatment.
    J Neuroimmunol. 2015;285:13-5.
    PubMed     Text format     Abstract available


    July 2015
  103. MUTO M, Mori M, Hiwasa T, Takiguchi M, et al
    Novel serum autoantibodies against talin1 in multiple sclerosis: Possible pathogenetic roles of the antibodies.
    J Neuroimmunol. 2015;284:30-6.
    PubMed     Text format     Abstract available


  104. TSONIS AI, Zisimopoulou P, Lazaridis K, Tzartos J, et al
    MuSK autoantibodies in myasthenia gravis detected by cell based assay - A multinational study.
    J Neuroimmunol. 2015;284:10-7.
    PubMed     Text format     Abstract available


    June 2015
  105. AKAISHI T, Nakashima I, Misu T, Fujihara K, et al
    Depressive state and chronic fatigue in multiple sclerosis and neuromyelitis optica.
    J Neuroimmunol. 2015;283:70-3.
    PubMed     Text format     Abstract available


  106. FERRARO D, Galli V, Vitetta F, Simone AM, et al
    Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis.
    J Neuroimmunol. 2015;283:64-9.
    PubMed     Text format     Abstract available


  107. PASQUALI L, Pecori C, Chico L, Iudice A, et al
    Relation between plasmatic and cerebrospinal fluid oxidative stress biomarkers and intrathecal Ig synthesis in Multiple Sclerosis patients.
    J Neuroimmunol. 2015;283:39-42.
    PubMed     Text format     Abstract available


  108. ZILKHA-FALB R, Gurevich M, Hayardeny L, Achiron A, et al
    The role of laquinimod in modulation of the immune response in relapsing-remitting multiple sclerosis: Lessons from gene expression signatures.
    J Neuroimmunol. 2015;283:11-6.
    PubMed     Text format     Abstract available


    May 2015
  109. BERGER B, Baumgartner A, Rauer S, Mader I, et al
    Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
    J Neuroimmunol. 2015;282:118-22.
    PubMed     Text format     Abstract available


  110. BASHINSKAYA VV, Kulakova OG, Kiselev IS, Baulina NM, et al
    GWAS-identified multiple sclerosis risk loci involved in immune response: Validation in Russians.
    J Neuroimmunol. 2015;282:85-91.
    PubMed     Text format     Abstract available


  111. CIERNY D, Hanysova S, Michalik J, Kantorova E, et al
    Genetic variants in interleukin 7 receptor alpha chain (IL-7Ra) are associated with multiple sclerosis risk and disability progression in Central European Slovak population.
    J Neuroimmunol. 2015;282:80-4.
    PubMed     Text format     Abstract available


  112. WEISHAUPT A, Paulsen D, Werner S, Wolf N, et al
    The T cell-selective IL-2 mutant AIC284 mediates protection in a rat model of Multiple Sclerosis.
    J Neuroimmunol. 2015;282:63-72.
    PubMed     Text format     Abstract available


  113. SERRANO-PERTIERRA E, Blanco-Gelaz MA, Oliva-Nacarino P, Martinez-Camblor P, et al
    Increased natural killer cell chemotaxis to CXCL12 in patients with multiple sclerosis.
    J Neuroimmunol. 2015;282:39-44.
    PubMed     Text format     Abstract available


  114. BARANOWSKA-BIK A, Kochanowski J, Uchman D, Litwiniuk A, et al
    Association of copeptin and cortisol in newly diagnosed multiple sclerosis patients.
    J Neuroimmunol. 2015;282:21-4.
    PubMed     Text format     Abstract available


  115. VISWANATHAN S, Wong AH, Quek AM, Yuki N, et al
    Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
    J Neuroimmunol. 2015;282:92-6.
    PubMed     Text format     Abstract available


  116. QUAN C, ZhangBao J, Lu J, Zhao C, et al
    The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy.
    J Neuroimmunol. 2015;282:45-53.
    PubMed     Text format     Abstract available


    April 2015
  117. DWYER MG, Zivadinov R, Markovic-Plese S, Bergsland N, et al
    Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly.
    J Neuroimmunol. 2015;281:44-50.
    PubMed     Text format     Abstract available


  118. CORREALE J, Farez MF
    Smoking worsens multiple sclerosis prognosis: Two different pathways are involved.
    J Neuroimmunol. 2015;281:23-34.
    PubMed     Text format     Abstract available


  119. EMAMI ALEAGHA MS, Siroos B, Ahmadi M, Balood M, et al
    Decreased concentration of Klotho in the cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2015;281:5-8.
    PubMed     Text format     Abstract available


  120. LI H, Dai Y, Wu AM, Sun X, et al
    Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders.
    J Neuroimmunol. 2015;281:38-43.
    PubMed     Text format     Abstract available


    March 2015
  121. MAMELI G, Cossu D, Cocco E, Frau J, et al
    Epitopes of HERV-Wenv induce antigen-specific humoral immunity in multiple sclerosis patients.
    J Neuroimmunol. 2015;280:66-8.
    PubMed     Text format     Abstract available


  122. VANDERLOCHT J, Hellings N
    Comment on "Dysregulated production of leukemia inhibitory factor in immune cells of relapsing remitting multiple sclerosis patients" by Levy et al. J. Neuroimmunol. 2015 Jan 15; 278C:85-89.
    J Neuroimmunol. 2015;280:56-7.
    PubMed     Text format    


  123. HAGMAN S, Kolasa M, Basnyat P, Helminen M, et al
    Analysis of apoptosis-related genes in patients with clinically isolated syndrome and their association with conversion to multiple sclerosis.
    J Neuroimmunol. 2015;280:43-8.
    PubMed     Text format     Abstract available


  124. ROSJO E, Myhr KM, Loken-Amsrud KI, Bakke SJ, et al
    Vitamin D status and effect of interferon-beta1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2015;280:21-8.
    PubMed     Text format     Abstract available


  125. MULERO P, Almansa R, Neri MJ, Bermejo-Martin JF, et al
    Improvement of fatigue in multiple sclerosis by physical exercise is associated to modulation of systemic interferon response.
    J Neuroimmunol. 2015;280:8-11.
    PubMed     Text format     Abstract available


  126. PEELEN E, Muris AH, Damoiseaux J, Knippenberg S, et al
    GM-CSF production by CD4(+) T cells in MS patients: Regulation by regulatory T cells and vitamin D.
    J Neuroimmunol. 2015;280:36-42.
    PubMed     Text format     Abstract available


  127. SUN Y, Chen H, Dai J, Zou H, et al
    HMGB1 expression patterns during the progression of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2015;280:29-35.
    PubMed     Text format     Abstract available


  128. AIVO J, Hanninen A, Ilonen J, Soilu-Hanninen M, et al
    Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta.
    J Neuroimmunol. 2015;280:12-5.
    PubMed     Text format     Abstract available


    February 2015
  129. PERGA S, Montarolo F, Martire S, Berchialla P, et al
    Anti-inflammatory genes associated with multiple sclerosis: A gene expression study.
    J Neuroimmunol. 2015;279:75-8.
    PubMed     Text format     Abstract available


  130. NIINO M, Sato S, Fukazawa T, Masaki K, et al
    Decreased serum vitamin D levels in Japanese patients with multiple sclerosis.
    J Neuroimmunol. 2015;279:40-5.
    PubMed     Text format     Abstract available


  131. BHARGAVA P, Gocke A, Calabresi PA
    1,25-Dihydroxyvitamin D3 impairs the differentiation of effector memory T cells in vitro in multiple sclerosis patients and healthy controls.
    J Neuroimmunol. 2015;279:20-4.
    PubMed     Text format     Abstract available


  132. NISCHWITZ S, Wolf C, Andlauer TF, Czamara D, et al
    MS susceptibility is not affected by single nucleotide polymorphisms in the MMP9 gene.
    J Neuroimmunol. 2015;279:46-9.
    PubMed     Text format     Abstract available


  133. TINGJUN C, Zhaohui L, Zhaocai J, Zihao L, et al
    Changes of CXCL12, CXCL14 and PDGF levels in the brain of patients with idiopathic demyelinating optic neuritis and neuromyelitis optica.
    J Neuroimmunol. 2015;279:1-6.
    PubMed     Text format     Abstract available


    January 2015
  134. WALKER-CAULFIELD ME, Hatfield JK, Brown MA
    Dynamic changes in meningeal inflammation correspond to clinical exacerbations in a murine model of relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2015;278:112-22.
    PubMed     Text format     Abstract available


  135. LEVY YA, Mausner-Fainberg K, Vaknin-Dembinsky A, Amidror T, et al
    Dysregulated production of leukemia inhibitory factor in immune cells of relapsing remitting multiple sclerosis patients.
    J Neuroimmunol. 2015;278:85-9.
    PubMed     Text format     Abstract available


  136. PASQUALI L, Lucchesi C, Pecori C, Metelli MR, et al
    A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
    J Neuroimmunol. 2015;278:53-9.
    PubMed     Text format     Abstract available


  137. ERIKSEN AB, Berge T, Gustavsen MW, Leikfoss IS, et al
    Retinoic acid enhances the levels of IL-10 in TLR-stimulated B cells from patients with relapsing-remitting multiple sclerosis.
    J Neuroimmunol. 2015;278:11-8.
    PubMed     Text format     Abstract available


  138. DELMAN D, Peng X, Zedek DC, Jewells V, et al
    Dermatomyositis as a presentation of neuromyelitis optica spectrum disorder.
    J Neuroimmunol. 2015;278:108-11.
    PubMed     Text format     Abstract available


  139. LI YJ, Zhang F, Qi Y, Chang GQ, et al
    Association of circulating follicular helper T cells with disease course of NMO spectrum disorders.
    J Neuroimmunol. 2015;278:239-46.
    PubMed     Text format     Abstract available


    December 2014
  140. MARNETTO F, Granieri L, Valentino P, Capobianco M, et al
    CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept study.
    J Neuroimmunol. 2014;277.
    PubMed     Text format     Abstract available


    November 2014
  141. GREY NEE COTTE S, Salmen Nee Stroet A, von Ahsen N, Starck M, et al
    Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
    J Neuroimmunol. 2014 Nov 20. pii: S0165-5728(14)00978.
    PubMed     Text format     Abstract available


  142. REIBER H, Kruse-Sauter H, Quentin CD
    Antibody patterns vary arbitrarily between cerebrospinal fluid and aqueous humor of the individual multiple sclerosis patient: Specificity-independent pathological B cell function.
    J Neuroimmunol. 2014 Nov 20. pii: S0165-5728(14)00959.
    PubMed     Text format     Abstract available


  143. JUREWICZ A, Zaleski K, Domowicz M, Selmaj K, et al
    High CD6 and low chemokine receptor expression on peripheral blood lymphocytes correlates with MRI gadolinium enhancement in MS.
    J Neuroimmunol. 2014;276.
    PubMed     Text format     Abstract available


  144. AUNG LL, Mouradian MM, Dhib-Jalbut S, Balashov KE, et al
    MMP-9 expression is increased in B lymphocytes during multiple sclerosis exacerbation and is regulated by microRNA-320a.
    J Neuroimmunol. 2014 Nov 10. pii: S0165-5728(14)00950.
    PubMed     Text format     Abstract available


  145. SERANA F, Chiarini M, Sottini A, Bertoli D, et al
    Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    J Neuroimmunol. 2014;277.
    PubMed     Text format     Abstract available


    October 2014
  146. COSENTINO M, Zaffaroni M, Marino F
    Levels of mRNA for dopaminergic receptor D in circulating lymphocytes may be associated with subsequent response to interferon-beta in patients with multiple sclerosis.
    J Neuroimmunol. 2014;277.
    PubMed     Text format     Abstract available


  147. MEYERS L, Groover CJ, Douglas J, Lee S, et al
    A role for Apolipoprotein A-I in the pathogenesis of multiple sclerosis.
    J Neuroimmunol. 2014;277.
    PubMed     Text format     Abstract available


  148. BURMAN J, Svensson E, Fransson M, Loskog AS, et al
    The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention.
    J Neuroimmunol. 2014;277.
    PubMed     Text format     Abstract available


  149. BERGER T, Jacobi C, Haas J, Ransmayr G, et al
    Predicting therapeutic efficacy of intravenous immunoglobulin (IVIG) in individual patients with relapsing remitting multiple sclerosis (RRMS) by functional genomics.
    J Neuroimmunol. 2014;277.
    PubMed     Text format     Abstract available


    September 2014
  150. POLAK PE, Lin SX, Pelligrino D, Feinstein DL, et al
    The blood-brain barrier-permeable catechol-O-methyltransferase inhibitor dinitrocatechol suppresses experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2014 Sep 16. pii: S0165-5728(14)00880.
    PubMed     Text format     Abstract available


  151. NYTROVA P, Potlukova E, Kemlink D, Woodhall M, et al
    Complement activation in patients with neuromyelitis optica.
    J Neuroimmunol. 2014;274.
    PubMed     Text format     Abstract available


  152. WEI Q, Yanyu C, Rui L, Caixia L, et al
    Human aquaporin 4 gene polymorphisms in Chinese patients with neuromyelitis optica.
    J Neuroimmunol. 2014;274.
    PubMed     Text format     Abstract available


  153. GUSTAVSEN MW, Viken MK, Celius EG, Berge T, et al
    Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general.
    J Neuroimmunol. 2014;274.
    PubMed     Text format     Abstract available


    July 2014
  154. ABRAMOWSKI P, Steinbach K, Zander AR, Martin R, et al
    Immunomodulatory effects of the ether phospholipid edelfosine in experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2014 Jul 21. pii: S0165-5728(14)00222.
    PubMed     Text format     Abstract available


  155. LEE DH, Rotger C, Appeldoorn CC, Reijerkerk A, et al
    Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2014 Jul 6. pii: S0165-5728(14)00196.
    PubMed     Text format     Abstract available


    June 2014
  156. YIN L, Chen Y, Qu Z, Zhang L, et al
    Involvement of JAK/STAT signaling in the effect of cornel iridoid glycoside on experimental autoimmune encephalomyelitis amelioration in rats.
    J Neuroimmunol. 2014 Jun 28. pii: S0165-5728(14)00193.
    PubMed     Text format     Abstract available


  157. WATANABE M, Kondo T, Murakata K, Kageyama T, et al
    Antibodies to neural and non-neural autoantigens in Japanese patients with CNS demyelinating disorders.
    J Neuroimmunol. 2014 Jun 27. pii: S0165-5728(14)00191.
    PubMed     Text format     Abstract available


  158. WEGMANN KW, Archie Bouwer HG, Whitham RH, Hinrichs DJ, et al
    Eluding anaphylaxis allows peptide-specific prevention of the relapsing stage of experimental autoimmune encephalomyelitis.
    J Neuroimmunol. 2014 Jun 26. pii: S0165-5728(14)00182.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: